ABOS Acumen Pharmaceuticals, Inc.

Overview and Growth

Acumen Pharmaceuticals, Inc. recorded fiscal 2025 net loss of $121.33M. The company reported diluted EPS of -$2.00, adding a shareholder-level measure to the absolute income figures considered below. The diluted weighted-average share count was 60.56M, linking total earnings with the per-share result received by shareholders. Diluted shares moved 0.9% from 60.01M in fiscal 2024, leaving the current share base higher year over year. The company employed $122.83M of total assets, the balance-sheet base supporting its current operating and cash-flow results.

Profitability

The reported operating result was an operating loss of $123.83M, reflecting costs that exceeded gross profit. The bottom-line result was a net loss of $121.33M after operating, financing, tax, and other recognized items. Negative EBITDA totaled $123.77M, confirming that the earnings deficit remained before depreciation and amortization. The company recognized $0.00 of income tax for the period, completing the transition from pretax income to net income. The net loss equaled 172.3% of period-end equity, showing the deficit relative to book capital. Relative to total assets, the net loss represented 98.8%. Compared with a $102.33M net loss in fiscal 2024, the current loss increased to $121.33M.

Liquidity and Capital Structure

Total assets were $122.83M, supported by $52.40M of liabilities and $70.43M of shareholder equity. The near-term balance sheet paired $122.25M of current assets with $30.01M of current liabilities at the reporting date. At 4.07x, the current ratio shows that short-term assets were greater than short-term liabilities at period end. Cash and equivalents totaled $53.99M, identifying the most liquid reported component available within the broader current-asset balance. The cash balance equaled 179.9% of current liabilities, showing how much near-term coverage came from cash alone. Borrowings totaled $31.16M, adding a fixed financing obligation alongside the company’s equity capital. Against book equity, debt measured 0.44x, placing the company’s financial leverage in clear balance-sheet terms. Relative to total assets, debt measured 25.4%, showing how much of the asset base was matched by borrowing. Equity equaled 57.3% of assets, showing the shareholder-capital layer within the company’s balance sheet. Liabilities represented 42.7% of total assets, quantifying the liability-funded share of the company’s resource base. The cash-to-assets relationship was 44.0%, comparing reported cash and equivalents with the full positive asset balance. Compared with $238.99M in fiscal 2024, the current asset base moved 48.6% and finished lower. Book equity was 61.3% lower than fiscal 2024 equity of $181.82M, showing how shareholder capital changed year over year. The reported cash balance changed 51.5% from $35.63M in fiscal 2024, ending higher year over year.

Cash Flow and Earnings Quality

Operating activities used $115.54M of cash, resulting in an operating cash outflow for the year. Capital expenditures used $88.00K in addition to the operating cash outflow, increasing the total cash consumed by operations and investment during the period. Operating cash flow and capital spending combined to leave a $115.63M cash deficit after capital spending. Relative to total assets, the post-investment cash deficit measured 94.1%. Compared with a $86.22M operating cash outflow in fiscal 2024, the current outflow increased to $115.54M.

Based on the annual report for the fiscal year ending Dec 31, 2025. Analysis generated Oct 21, 2026.